What causes a prolactinoma to develop on the pituitary gland? 

A prolactinoma is a benign tumour of the pituitary gland that causes the overproduction of the hormone prolactin. While the exact reason why these tumours begin to form in some individuals and not others remains a subject of ongoing clinical research, it is understood that they arise from a specific type of cell called a lactotroph. These cells, located in the anterior pituitary, normally produce prolactin in response to signals from the brain. In the case of a prolactinoma, a single lactotroph cell undergoes a genetic change that causes it to multiply uncontrollably, forming a small clump of tissue known as an adenoma. In the United Kingdom, these are the most common type of hormone secreting pituitary tumours, yet for the vast majority of patients, the development of the tumour is a spontaneous event with no single, identifiable external cause. 

What We’ll Discuss in This Article 

• The cellular origin of prolactinomas in the anterior pituitary gland. 

• The role of spontaneous genetic mutations in tumour development. 

• Hereditary factors and genetic syndromes such as MEN1. 

• How the disruption of the dopamine “brake” contributes to growth. 

• The influence of hormonal factors and environmental triggers. 

• Common diagnostic markers and how they relate to tumour cause. 

• Answers to frequently asked questions about prolactinoma risk factors. 

The cellular origin and development of lactotroph adenomas 

The development of a prolactinoma begins with the lactotroph cells, which are responsible for the synthesis and secretion of prolactin. Under normal circumstances, the growth and activity of these cells are tightly regulated by the hypothalamus. However, a prolactinoma develops when one of these cells acquires a mutation that allows it to bypass these regulatory signals. This single “rogue” cell begins to clone itself, eventually creating a mass of identical cells that all produce prolactin. Because these cells are identical, the resulting tumour is referred to as monoclonal in origin. 

In most cases diagnosed in the UK, these tumours are classified as microprolactinomas, meaning they are less than 10 millimetres in diameter. While they are small, their impact is significant because every cell within the tumour is actively pumping prolactin into the bloodstream. The NHS guidance on pituitary tumours clarifies that these are benign growths, not cancers, meaning they do not spread to other parts of the body. The primary clinical concern is not the growth of the tumour itself, but the systemic effects of the hormone excess it creates. 

Spontaneous genetic mutations as a primary cause 

For approximately 95 percent of people with a prolactinoma, the tumour develops sporadically, meaning there is no family history of the condition. Scientists believe that these cases are caused by spontaneous mutations in the DNA of a pituitary cell that occur during a person’s lifetime. These mutations often affect the genes that control cell division or the receptors that receive signals from the hypothalamus. When these “off switches” for cell growth are damaged, the cell continues to divide when it should remain dormant. 

Specific research published in UK clinical journals has identified certain proteins and signalling pathways that are frequently overactive in prolactinoma cells. For example, mutations may occur in genes that regulate the cell’s response to dopamine, the chemical that normally stops prolactin production. If the cell loses its ability to “hear” the dopamine signal, it effectively becomes an autonomous hormone factory. Despite these cellular insights, there is currently no evidence that lifestyle factors, diet, or environmental pollutants trigger these specific mutations. 

Hereditary factors and Multiple Endocrine Neoplasia (MEN1) 

While most prolactinomas are spontaneous, a small percentage are linked to inherited genetic syndromes. The most prominent of these is Multiple Endocrine Neoplasia type 1, or MEN1. This is a rare hereditary condition where individuals have a mutation in the MEN1 gene, which normally acts as a tumour suppressor. People with this syndrome have a significantly higher risk of developing tumours in the pituitary gland, as well as in the parathyroid glands and the pancreas. 

In the UK, if a patient is diagnosed with a prolactinoma at a very young age or has a strong family history of endocrine tumours, clinicians may recommend genetic testing for MEN1. According to the Society for Endocrinology, prolactinomas associated with MEN1 tend to be more aggressive and larger than those that occur sporadically. Another rare genetic cause is Familial Isolated Pituitary Adenomas (FIPA), where pituitary tumours run in families without the other features of MEN1. Identifying a genetic cause is important for the long term monitoring of the patient and their family members. 

The disruption of the dopamine inhibitory pathway 

The relationship between the hypothalamus and the pituitary gland is fundamental to understanding why prolactinomas thrive. The hypothalamus produces dopamine, which travels through the pituitary stalk to keep prolactin levels low. If this pathway is disrupted, it can encourage the growth of lactotroph cells. While the tumour itself is caused by a mutation, the environment in which it grows is influenced by this dopamine “brake.” 

In some clinical scenarios, a “pseudo prolactinoma” can develop. This occurs when a different type of large, non-functioning pituitary tumour presses against the pituitary stalk. This physical pressure blocks the flow of dopamine from the brain to the gland. Without the inhibitory effect of dopamine, the normal lactotroph cells begin to produce more prolactin, leading to a mild rise in blood levels. This is known as the “stalk effect.” It is vital for UK specialists to distinguish between a true prolactinoma (a tumour made of prolactin cells) and a rise in prolactin caused by the stalk effect, as the treatment for each is entirely different. 

The influence of oestrogen and hormonal changes 

There has been significant clinical discussion regarding whether oestrogen levels can cause a prolactinoma to develop or grow. Prolactinomas are much more commonly diagnosed in women of childbearing age than in men, leading to the theory that female sex hormones may play a role in their development. Oestrogen is known to stimulate the growth of lactotroph cells and increase prolactin production, which is a normal process during pregnancy. 

However, current evidence from UK clinical practice suggests that while oestrogen can cause an existing prolactinoma to enlarge slightly particularly during pregnancy it is not the primary cause of the tumour’s initial formation. Most women with prolactinomas find that their tumours remain stable or even shrink after the menopause when oestrogen levels naturally decline. Furthermore, the use of the combined oral contraceptive pill has not been proven to cause prolactinomas in the general population. 

Distinguishing causes from secondary triggers 

It is important for patients to understand the difference between the cause of a tumour and things that can temporarily raise prolactin levels. Many factors can cause “hyperprolactinaemia” (high prolactin) without a tumour being present. Certain medications, particularly antipsychotics, some antidepressants, and anti sickness drugs, work by blocking dopamine in the brain. Because they remove the dopamine “brake,” they can cause prolactin levels to rise significantly, sometimes mimicking the symptoms of a prolactinoma. 

Other triggers for temporary prolactin elevation include physical stress, nipple stimulation, and certain underlying health conditions like an underactive thyroid (hypothyroidism) or chronic kidney disease. In the UK, a GP will usually exclude these secondary causes with blood tests before referring a patient for an MRI scan to look for a tumour. Finding a high prolactin level does not automatically mean a tumour has developed; it is the combination of biochemical evidence and imaging that confirms the presence of a prolactinoma. 

Conclusion 

A prolactinoma develops on the pituitary gland when a single lactotroph cell undergoes a spontaneous genetic mutation, causing it to multiply and overproduce prolactin. While most cases are sporadic and have no known external trigger, a small percentage are linked to inherited genetic syndromes like MEN1. Disruption of the dopamine inhibitory pathway also plays a key role in the environment that allows these tumours to function. Diagnosis in the UK focuses on distinguishing these benign growths from other causes of high prolactin to ensure appropriate treatment. If you experience severe, sudden, or worsening symptoms, call 999 immediately. 

Authority Snapshot 

This article provides a clinical overview of the causes and development of prolactinomas to support patient education in the United Kingdom. The content has been authored by a specialized medical content team and reviewed by Dr. Rebecca Fernandez to ensure clinical precision and safety. All information is strictly aligned with the latest NHS guidelines and British endocrine society standards to provide reliable information for patients.